Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Long-term follow-up allays fears that finasteride increases mortality

Initial concerns that finasteride could increase risk of prostate cancer death have been found to be unwarranted in a long-term follow-up study.

Prostate cancer cells


During an 18 year follow-up there were 42 deaths from prostate cancer (cells pictured) in the finasteride group and 56 deaths in the placebo group

Follow-up of patients who took part in the Prostate Cancer Prevention Trial showed that finasteride was not associated with an increased risk of death from the disease compared with placebo, as was previously thought[1].

In total, 18,882 men were randomly assigned to finasteride or placebo for seven years. Mortality data were extracted from a national database of deaths.

During median follow-up of 18.4 years, there were 42 (0.45%) deaths from prostate cancer in the finasteride group and 56 (0.59%) deaths in the placebo group. This equated to a non-significant 25% reduced risk of prostate cancer death.

In the original seven-year trial, finasteride was associated with a reduced risk of prostate cancer overall, but an increased risk of high-grade prostate tumours, which led to concerns that it would either increase mortality or have no effect on prostate cancer survival.

The researchers, who published the findings in the New England Journal of Medicine (24 January 2019), said these concerns were unwarranted and use of the drug could prevent men from undergoing invasive surgery or the anxiety of watchful waiting.

“The best-case scenario for patients is prevention, and this trial has found an inexpensive medication that gets us there,” said principal investigator Ian Thompson from the Santa Rosa Hospital Medical Center, San Antonio, Texas.

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206193

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.